Phase 4 N=22 Special Access Program IMVAMUNE®
Vaccination
Primary: ELISA Seropositivity Rate — 40.9; 100.0 percentage of subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=52 Combination Vaccination Before HIV Treatment Interruption
HIV Infections
Primary: Time to Detectable Virus in the Remune Plus ALVAC Group and the Placebo Group — 24.5; 13.5 days
Phase 4 N=3,032 VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV
Smallpox Vaccine Adverse Reaction
Primary: Number of Vaccinated Participants With Adverse Events (AEs) Including Serious Adverse Events (SAEs) — 1420 Participants
Phase 3 N=1,250 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)
Bacterial Infections · Virus Diseases
Primary: Percentage of Participants Vaccinated With PR5I With Acceptable Antibody (Ab) Response to Haemophilus Influenzae Type b, Diphtheria, Tetanus, and Poliovirus Types 1, 2 &…
Phase 2 N=58 Vaccination of High Risk Breast Cancer Patients
Breast Cancer · Breast Neoplasms
Primary: Identify a Feasible Schedule of Vaccination Relative to SoC Neoadjuvant Chemotherapy When the Chemovax Are Administered Concurrently. — 3; 2; 4; 2 Participants
Phase 4 N=48 VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)
Chronic Heart Failure
Primary: Number of Participants With 4 Fold Rise in Serum Antibody Concentration of A/H1N1 Vaccine Antigens — 11; 12 Participants — p=0.89
Phase 3 N=207 A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)
Hepatitis B
Primary: Percentage of Participants With a Protective Hepatitis B Surface Antibody Level of ≥10 Milli International Units/mL (mIU/mL) at 30 Days Post-Challenge With HBVAXPRO™…
Phase 2 N=30 Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections
Cystic Fibrosis · Bronchiectasis Adult · Non-Tuberculous Mycobacteria
Primary: BCG Uptake — 48.06; 0.84; 35.97 spot forming units
N/A N=87,665 From Innovation to Solutions: Childhood Influenza Vaccination Planning
Influenza
Primary: Primary Outcome — 26432; 19352 participants vaccinated out of all — p=<0.05
Phase 3 N=498 Simplifying the Rabies Pre-exposure Vaccination
Rabies
Primary: Number of Participants With a Boostability of the Rabies Antibodies After Booster Vaccination — 185; 183 Participants
N/A N=510 Promoting Altruism to Enhance Vaccine Acceptance
Vaccine Refusal
Primary: Change in Vaccine Hesitancy Scores Pre- and Post-Intervention. — -0.4 units on a scale
Phase 2 N=71 Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
Relapsing Forms of Multiple Sclerosis
Primary: Percentage of Tetanus Responders (≥ 2-Fold Rise) at Day 28 Compared to Prevaccination Level — 73; 68 percentage of participants — p=0.692
Phase 3 N=80 A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069)
Hepatitis A Virus Infection
Primary: Hepatitis A Virus (HAV) Seroconversion Rate, i.e. the Percentage of Subjects Who Were Seronegative at Baseline and Developed Seropositive at Month 7 After Administration…
Phase 4 N=66 Vaccination for Recovered Inpatients With COVID-19 (VATICO)
Covid19
Primary: Ratio of 48-Week to Baseline Neutralizing Antibody (NAb) Levels — 0.3722; 0.5883; 0.2088; 0.3073 ratio of geometric mean responses
Phase 4 N=20 Immune Response Following Seasonal Influenza Vaccination
Influenza
Primary: HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain — 293.4 Geometric Mean Titer
Phase 1 N=6 Vaccination of High Risk Breast Cancer Patients
Stage IV Breast Cancer
Primary: Number of Participants With a Dose-limiting Toxicity (Defined as an Adverse Event of Grade 3 or Higher) — 0; 0 participants
N/A N=60 VISTA: Vaccinator-Initiated Screening and TAilored Counseling for Reducing Vaccine Hesitancy
Vaccination Uptake
Primary: Percentage of Women With Reduced Number of Concerns Immediately Post-counseling in the Intervention Arm — 51.72 percentage of women
Phase 1 N=39 Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)
Ebola Virus
Primary: Number of Participants With One or More Solicited Local Treatment-Emergent Adverse Events (TEAE) — 8; 8; 10; 3 Participants
N/A N=546 A Randomized Trial of Vaccine Adherence in Young Injection Drug Users
Medication Adherence · Substance Abuse, Intravenous · Risk Behavior
Primary: Vaccine Series Completion — 16; 20; 8; 10 participants
N/A N=544 Feasibility of Cocooning Immunization Strategy With Influenza Vaccine
Influenza
Primary: Influenza Vaccine Coverage (Percent) for New Mothers of Newborns — 70; 64 Percentage of Participants
Phase 1 N=185 Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Solicited Local Adverse Events (AE) During 7 Days After Vaccination — 5; 9; 16; 19 Participants
N/A N=228,831 Precision Vaccine Promotion in Underserved Populations
Influenza · Vaccine Hesitancy
Primary: Number of Participants Vaccinated at the End of the Campaign Period — 33357; 854 Participants — p=0.216
N/A N=300 Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-1).
Type 1 Diabetes Mellitus
Primary: Adherence to Regional Guidelines for the Immunization of Adults With Type 1 Diabetes Mellitus (T1DM — 165; 54; 51; 30 Participants
Phase 2 N=36 Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
HIV-1 Infection
Primary: Part A: To Establish Highest Tolerated Dose of Lenalidomide, Dose-Limiting Toxicity — 0; 0; 0 Participants
Phase 3 N=1,315 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Bacterial Infections · Virus Diseases
Primary: Acceptability of Antibody (Ab) Response or Seroresponse Rates to All Antigens Contained in PR5I Vaccine One Month After the Toddler Dose of PR5I (11 to 12 Months of Age)…
Phase 4 N=59 Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis
Rabies
Primary: Protective Humoral Immune Response at 1 Month Post First Vaccination. — 12; 12; 12; 11 Participants
N/A N=33 Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination
HIV · Rabies
Primary: Rabies Neutralizing Antibody Titers — 8.48 IU/ml
Phase 1 N=99 Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Adverse Events of Special Interest (AESIs) From Study Vaccination Through the End of the Study — 1; 3; 2; 0 Participants
Phase 2 N=33 Re-boosting of HIV-1 Infected Subjects With Vacc-4x
HIV-1 Infection
Primary: Vacc-4x Effect on Viral Load Set-point — 38455.0; 40088.8; 45253.9; 47336.8 Copies/mL
Phase 4 N=165 Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders
Plasma Cell Neoplasm
Primary: Seroprotection Based on Hemagglutination Antibody Inhibition (HAI) — 32; 22 Participants